Logo

Log In Sign Up |  An official publication of: American College of Emergency Physicians
Navigation
  • Home
  • Multimedia
    • Podcasts
    • Videos
  • Clinical
    • Airway Managment
    • Case Reports
    • Critical Care
    • Guidelines
    • Imaging & Ultrasound
    • Pain & Palliative Care
    • Pediatrics
    • Resuscitation
    • Trauma & Injury
  • Resource Centers
    • mTBI Resource Center
  • Career
    • Practice Management
      • Benchmarking
      • Reimbursement & Coding
      • Care Team
      • Legal
      • Operations
      • Quality & Safety
    • Awards
    • Certification
    • Compensation
    • Early Career
    • Education
    • Leadership
    • Profiles
    • Retirement
    • Work-Life Balance
  • Columns
    • ACEP4U
    • Airway
    • Benchmarking
    • Brief19
    • By the Numbers
    • Coding Wizard
    • EM Cases
    • End of the Rainbow
    • Equity Equation
    • FACEPs in the Crowd
    • Forensic Facts
    • From the College
    • Images in EM
    • Kids Korner
    • Medicolegal Mind
    • Opinion
      • Break Room
      • New Spin
      • Pro-Con
    • Pearls From EM Literature
    • Policy Rx
    • Practice Changers
    • Problem Solvers
    • Residency Spotlight
    • Resident Voice
    • Skeptics’ Guide to Emergency Medicine
    • Sound Advice
    • Special OPs
    • Toxicology Q&A
    • WorldTravelERs
  • Resources
    • ACEP.org
    • ACEP Knowledge Quiz
    • Issue Archives
    • CME Now
    • Annual Scientific Assembly
      • ACEP14
      • ACEP15
      • ACEP16
      • ACEP17
      • ACEP18
      • ACEP19
    • Annals of Emergency Medicine
    • JACEP Open
    • Emergency Medicine Foundation
  • About
    • Our Mission
    • Medical Editor in Chief
    • Editorial Advisory Board
    • Awards
    • Authors
    • Article Submission
    • Contact Us
    • Advertise
    • Subscribe
    • Privacy Policy
    • Copyright Information

Drugs for Immediate Relief of Cannabinoid Hyperemesis Syndrome

By Lauren Westafer, DO | on February 24, 2021 | 3 Comments
Practice Changers
  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
Print-Friendly Version
shutterstock.com
shutterstock.com

Editors’ Note: Looking to learn something new to improve patient care? This new quarterly column breaks down recent research into practical tips you can use in everyday practice. 

You Might Also Like
  • Intoxication from Synthetic-Cannabinoid-Receptor Agonists Often Missed
  • Fentanyl Versus Ketamine for Intranasal Pain Relief
  • Acute Chest Syndrome in Pediatric Sickle-Cell Disease: Antibiotic Guidelines Matter
Explore This Issue
ACEP Now: Vol 40 – No 02 – February 2021

The department is filled with the sound of retching as you approach the room of the next patient, a 29-year-old male with nausea, vomiting, and abdominal pain. Although the patient received ondansetron in the ambulance, he is still uncomfortable. He reveals that he has had similar episodes of generalized abdominal pain, nausea, and vomiting in the past. Taking a hot shower sometimes helps. He has not had fevers or diarrhea, and his abdominal exam is benign. Before exiting the room, you have one remaining question to ask: Does he use marijuana, and if yes, how often? 

Cannabinoid Hyperemesis Syndrome

This is a classic case of cannabinoid hyperemesis syndrome (CHS). The treatment, cessation of marijuana use, will not provide immediate relief in the emergency department. So what do you do in the meantime?

CHS, first characterized in 2004, presents similarly to other cyclic vomiting syndromes.1 CHS is characterized by nausea, vomiting (classically described as cyclic), and abdominal pain in patients with chronic use of marijuana. Patients frequently report that hot showers relieve symptoms, and some have described compulsive bathing.2 For some, CHS seems at odds with the long-touted antiemetic properties of tetrahydrocannabinol (THC). How could an antiemetic cause a cyclic vomiting syndrome? 

The mechanism underlying CHS is not entirely clear, but it is believed that the gastrointestinal effects are a result of activation of cannabinoid 1 (CB1) receptors, which inhibit gastric emptying and motility. With chronic use, THC can at times emerge from adipose tissue and enter the bloodstream, potentially contributing to a bout.

In many instances, ondansetron does not suffice in treating CHS.3 Fortunately, the butyrophenones—haloperidol and droperidol—have emerged as promising treatments.  Reports of the success of haloperidol and droperidol have largely been documented in case series and retrospective studies.4 These medications have a track record of efficacy in postoperative nausea and migraine headaches, so it is credible that they might be effective in CHS. Until recently, the best available evidence was a retrospective study of patients who received droperidol, most of whom received 0.625 mg or 1.25 mg. Patients who received droperidol had a shorter length of stay (6.7 hours versus 13.9 hours).4 However, we now have a small prospective randomized trial comparing haloperidol to ondansetron in CHS, which was published in the Annals of Emergency Medicine.

Pages: 1 2 3 | Single Page

Topics: butyrophenonesCannabinoidcannabinoid hyperemesis syndromecapsaicindroperidolhaloperidolMarijuana

Related

  • Case Report: Uvular Edema in a Marijuana Smoker

    November 5, 2024 - 0 Comment
  • Toxicology Answer: The Capsaicin Found in Hot Peppers and Chilis

    April 2, 2024 - 0 Comment
  • Toxicology Question: What Fiery Ingredient Brings Tears to Your Eyes and Irritation Upon Exposure?

    April 1, 2024 - 0 Comment

Current Issue

ACEP Now: July 2025

Download PDF

Read More

3 Responses to “Drugs for Immediate Relief of Cannabinoid Hyperemesis Syndrome”

  1. February 28, 2021

    Edward L Fieg Reply

    In my experience, one of the hallmarks of Cannabis Hyperemesis Syndrome, is that the patient, minimiing their cannabis use, absolutely, positively, will not even consider to entertain any discussion of the possibility that the cannabis is the culprit.

  2. February 28, 2021

    Frank Fower,MD,FACEP Reply

    I have been using the same: Haldol or Inapsin to treat such cases even before 2004…
    I give 50 mg Benadryl IV with it , It’s Synergistic effect and prevents EPS and prevents prolongation of QT interval

    • November 28, 2024

      Isaac Okoni Reply

      Can soursop beverage help in alleviating CHS?

Leave a Reply Cancel Reply

Your email address will not be published. Required fields are marked *


*
*

Wiley
  • Home
  • About Us
  • Contact Us
  • Privacy
  • Terms of Use
  • Advertise
  • Cookie Preferences
Copyright © 2025 by John Wiley & Sons, Inc. All rights reserved, including rights for text and data mining and training of artificial technologies or similar technologies. ISSN 2333-2603